reference/35133488

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/35133488

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Clinical Trial, Phase I\|Journal Article
endingPage	452
issn	1099-1069 0278-0232
issueIdentifier	3
pageRange	442-452
publicationName	Hematological Oncology
startingPage	442
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_5286aa5c8db50b53ee48506a808597e4 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_26fba9456e1e33d5671ff7055ed23621
bibliographicCitation	Sunami K, Fuchida SI, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Imada K, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Onishi R, Tada K, Iida S. Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study. Hematol Oncol. 2023 Aug;41(3):442–52. doi: 10.1002/hon.3105. PMID: 36433829.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-0654-6920 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_27d5c109ebafea85225e6184b6b32b8c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dc6c2851ee2493a328ec58ff03b11edb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5cbec3d7c081cbe4479ce8a7a44fff8c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9672b6474ac5a341c878ea7c415913fd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cf453be36625ad19caa3d2a31c174194 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_48d74138183435658de3e7b952f1b11e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1efb9bfd0b6d4aa949ea8bf80d886054 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4951-960X http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d70be8810ea56084c75a31de3899b573 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0f970329f11724ca282d5e85f03bd504 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fb0edd11b9faa4ca87bc609ec8e2af4b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6495006e2f8c48d3032c54b03d59be21 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1fdbf0683363e439a96b36d6053b1cf3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-3976-5230 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7ea39740ccd67eb19b206019809b0a29 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c62ac67bacad346db5a95d45e729c1e1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9617-486X http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_08b9e0a9087b1b2a45dbf8f1b444ca97 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f51906f1567a282d9817a7af7e95524b
date	2022-12-15^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/36433829 https://doi.org/10.1002/hon.3105
isPartOf	https://portal.issn.org/resource/ISSN/1099-1069 https://portal.issn.org/resource/ISSN/0278-0232 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4074
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Anti‐CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study
discusses	http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0006099 http://id.nlm.nih.gov/mesh/M000635520
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D009101Q000473
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D003907 http://id.nlm.nih.gov/mesh/D061067Q000627 http://id.nlm.nih.gov/mesh/D000077982 http://id.nlm.nih.gov/mesh/D000095225 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D006801
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_6fab6bf193c862d5cac8dd80e83ceb7a http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8530 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7277

Showing number of triples: 1 to 55 of 55.